About Paul Stoffels, M.D.
Paul Stoffels, M.D. studied Medicine in Belgium and began his career as a physician in Africa, as part of the Janssen Research Foundation (JRF) under the mentorship of Dr. Paul Janssen, focusing on HIV and tropical diseases research. During this time, Paul witnessed first-hand the devastation being caused by a new and unknown disease - HIV, more commonly known as AIDS.
He founded a company named Tibotec to focus on HIV treatment and Virco, focused on diagnostics. As a result of this team's work, three leading products for the treatment of HIV were eventually developed - PREZISTA, INTELENCE and EDURANT. Paul Stoffels, M.D. joined Johnson & Johnson in 2002 and is currently the Chief Scientific Officer of Johnson & Johnson.
Global public health is a life-long passion for Paul Stoffels, M.D. . Under his leadership, Johnson & Johnson brought forward Bedaquiline - the first new drug for MDR-TB in more than four decades and launched a new Global Public Health strategy that leverages the Company's resources to improve health outcomes among vulnerable populations. He was instrumental in building the relationship between UNAIDS/WHO and the pharmaceutical industry with regard to the provision of HIV drugs in Africa. More recently, Paul Stoffels, M.D. has become a sought-after partner and thought leader on issues of anti-microbial resistance, pandemic preparedness, and access to medicines.